Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204639659> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W3204639659 endingPage "24" @default.
- W3204639659 startingPage "18" @default.
- W3204639659 abstract "Introduction: Various types of COVID 19 vaccine are being used globally to control the current pandemic. Post-licensure surveillance of vaccine is essential to ensure the safety. This study aimed to determine Adverse Events Following Immunization (AEFIs) of China Sinopharm (Vero cell), the inactivated COVID-19 vaccine.
 Method: This is a cross sectional observational study conducted at Patan hospital, Patan Academy of Health Sciences (PAHS) after the approval from IRC. Vaccine recipient between April 7 to April 13 and May 16 to May 25 were contacted through a phone call after 72 h of vaccination to record the AEFIs. Pattern and distribution of AEFIs were analyzed. Ethical approval was taken from PAHS IRC.
 Result: A total of 6142 individual got the first dose of the vaccine and out of them we were able to contact 4574 through phone calls. Of the 4574, only 941 were included for the follow up phone call after the second dose of the vaccine. A total of 1336 AEFIs were reported in 868(19%) first dose vaccine recipients while 147 AFEIs were reported in 105(11.2%) second dose vaccine recipients. The frequently reported AEFIs were pain at injection site, lethargy, headache, muscle ache and fever. All the AEFIs were mild to moderate in severity. Most of the AEFIs started within 24 h and resolved within 72 h.
 Conclusion: The Sinopharm (Vero cell) vaccine was found to have mild to moderate AEFIs in our study cohort and no case of severe AEFI was identified." @default.
- W3204639659 created "2021-10-11" @default.
- W3204639659 creator A5000069652 @default.
- W3204639659 creator A5006295926 @default.
- W3204639659 creator A5019579547 @default.
- W3204639659 creator A5026232332 @default.
- W3204639659 creator A5032120537 @default.
- W3204639659 creator A5042191786 @default.
- W3204639659 creator A5052096053 @default.
- W3204639659 creator A5053960605 @default.
- W3204639659 creator A5064225805 @default.
- W3204639659 creator A5068786280 @default.
- W3204639659 creator A5075128181 @default.
- W3204639659 creator A5079395672 @default.
- W3204639659 date "2021-09-28" @default.
- W3204639659 modified "2023-09-27" @default.
- W3204639659 title "Adverse events following Sinopharm (Vero Cell), the inactivated COVID-19" @default.
- W3204639659 doi "https://doi.org/10.3126/jpahs.v8i2.31099" @default.
- W3204639659 hasPublicationYear "2021" @default.
- W3204639659 type Work @default.
- W3204639659 sameAs 3204639659 @default.
- W3204639659 citedByCount "3" @default.
- W3204639659 countsByYear W32046396592022 @default.
- W3204639659 countsByYear W32046396592023 @default.
- W3204639659 crossrefType "journal-article" @default.
- W3204639659 hasAuthorship W3204639659A5000069652 @default.
- W3204639659 hasAuthorship W3204639659A5006295926 @default.
- W3204639659 hasAuthorship W3204639659A5019579547 @default.
- W3204639659 hasAuthorship W3204639659A5026232332 @default.
- W3204639659 hasAuthorship W3204639659A5032120537 @default.
- W3204639659 hasAuthorship W3204639659A5042191786 @default.
- W3204639659 hasAuthorship W3204639659A5052096053 @default.
- W3204639659 hasAuthorship W3204639659A5053960605 @default.
- W3204639659 hasAuthorship W3204639659A5064225805 @default.
- W3204639659 hasAuthorship W3204639659A5068786280 @default.
- W3204639659 hasAuthorship W3204639659A5075128181 @default.
- W3204639659 hasAuthorship W3204639659A5079395672 @default.
- W3204639659 hasBestOaLocation W32046396591 @default.
- W3204639659 hasConcept C126322002 @default.
- W3204639659 hasConcept C197934379 @default.
- W3204639659 hasConcept C203014093 @default.
- W3204639659 hasConcept C2522874641 @default.
- W3204639659 hasConcept C71924100 @default.
- W3204639659 hasConcept C89138240 @default.
- W3204639659 hasConceptScore W3204639659C126322002 @default.
- W3204639659 hasConceptScore W3204639659C197934379 @default.
- W3204639659 hasConceptScore W3204639659C203014093 @default.
- W3204639659 hasConceptScore W3204639659C2522874641 @default.
- W3204639659 hasConceptScore W3204639659C71924100 @default.
- W3204639659 hasConceptScore W3204639659C89138240 @default.
- W3204639659 hasIssue "2" @default.
- W3204639659 hasLocation W32046396591 @default.
- W3204639659 hasOpenAccess W3204639659 @default.
- W3204639659 hasPrimaryLocation W32046396591 @default.
- W3204639659 hasRelatedWork W2073975292 @default.
- W3204639659 hasRelatedWork W2348442726 @default.
- W3204639659 hasRelatedWork W2378938053 @default.
- W3204639659 hasRelatedWork W2466099832 @default.
- W3204639659 hasRelatedWork W2511940250 @default.
- W3204639659 hasRelatedWork W2748952813 @default.
- W3204639659 hasRelatedWork W2899084033 @default.
- W3204639659 hasRelatedWork W3031052312 @default.
- W3204639659 hasRelatedWork W3032375762 @default.
- W3204639659 hasRelatedWork W4303685175 @default.
- W3204639659 hasVolume "8" @default.
- W3204639659 isParatext "false" @default.
- W3204639659 isRetracted "false" @default.
- W3204639659 magId "3204639659" @default.
- W3204639659 workType "article" @default.